Maintaining a healthy gut microbiome is crucial.

Constipation and diarrhea are common gastrointestinal issues. With accelerated lifestyles and dietary changes, the incidence of chronic constipation and diarrhea is rising annually, becoming a silent killer of modern health.

In recent years, gut problems caused by constipation and diarrhea have increased. Beyond gastrointestinal dysfunction, the onset of certain cardiovascular and cerebrovascular diseases is also linked to these issues, thus drawing widespread attention to gut health.

Long-term constipation and diarrhea pose numerous health risks.

The hazards of constipation and diarrhea include:

1.  Imbalance of the gut microbiota, affecting skin health, inducing facial acne, and accelerating aging.
2.  Causing anxiety and depression, impacting mood and mental health.
3.  Leading to symptoms such as indigestion and bloating.
4.  Accumulation of toxins and waste in the intestines, potentially leading to intestinal diseases like polyps and colorectal cancer.
5.  For patients with cardiovascular and cerebrovascular diseases, constipation can induce cardiovascular and cerebrovascular accidents, even life-threatening events.
6.  Causing a sharp decrease in blood volume and increased blood viscosity, leading to thrombus formation and increasing the risk of myocardial infarction.

Bioyitech Functional Strain Promotes Intestinal Motility: Scientific Experiments

Invention Patent: A Subspecies of *Bifidobacterium animalis* Subsp. *lactis* F1-7 for Promoting Intestinal Motility and its Application

Patent Number: ZL202110565814.X

Objective of the Invention

*   To obtain a single strain with outstanding probiotic performance that can effectively promote intestinal motility.

*   To provide a subspecies of *Bifidobacterium animalis* subsp. *lactis* F1-7 for promoting intestinal motility and its application.

Validation Experiments

Animal experiments (zebrafish, mice) were divided into a normal group (N), a model group (M), a model + positive drug group (P), a model + LGG group, and a model + F1-7 group.

After incubating constipation-induced zebrafish with bacterial suspensions of each concentration at 10⁸ CFU/mL for 24 hours, the number of intestinal peristalses per unit time (1 min) in each group of zebrafish was observed under an inverted fluorescence microscope.

After inducing intestinal motility disorders in mice, a 20-day probiotic intervention was carried out. At the end of the intervention, the intestinal transit rate of the observed mice was measured.

N: Normal group, M: Model group, P: Model + positive drug group, LGG: Model + LGG group, F1-7: Model + F1-7 group

In the 1-minute intestinal motility observation:

Normal group (N): The first peristaltic wave peak in zebrafish intestinal motility appeared around 28s.

Model group (M): No peristalsis was observed within 1 minute.

Model + positive drug group (P): The first peristalsis appeared around 22s, and the second peristalsis appeared around 42s.

Model + LGG group (LGG): No peristalsis was observed within 1 minute.

Model + F1-7 group (F1-7): The first peristalsis appeared around 22s, and the second peristalsis appeared around 42s.

Conclusion: F1-7 promotes intestinal motility, outperforming the LGG group and comparable to the positive drug.

Intestinal Propulsion Effect of F1-7

N: Normal group, M: Model group, P: Model + positive drug group, LGG: Model + LGG group, F1-7: Model + F1-7 group

Intestinal propulsion rate:

Tested 15 minutes after feeding, intestinal propulsion rate = distance of food movement / total small intestine length 100%

Compared to the model group, F1-7 significantly promoted the intestinal transit rate in mice, increasing it from 1.04 ± 1.81% to 88.19 ± 4.10% (p < 0.01), reaching a level close to that of the positive drug and superior to the reference strain LGG.

Conclusion: The intestinal propulsion effect of Bifidobacterium animalis subsp. Lactis F1-7 is comparable to that of the positive drug, demonstrating a significant intestinal propulsive action.